Research shows drug can extend survival rates for heart failure patients

Researchers at the University of Arizona College of Medicine—Phoenix have shown for the first time in preclinical studies that Aliskiren, a drug that inhibits the enzyme that regulates blood pressure, can delay the progression of congestive heart failure and lengthen survival rates.